Listed

Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2013

Filed with the SEC on Feb 14, 2014 and accepted by EDGAR at Feb 14, 2014, 11:34 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2013-10-01 to 2013-12-31−$225.5kus-gaap:OperatingIncomeLoss
Operating income6 months2013-07-01 to 2013-12-31−$534.0kus-gaap:OperatingIncomeLoss
Interest expense3 months2013-10-01 to 2013-12-31$20.2kus-gaap:InterestExpense
Interest expense6 months2013-07-01 to 2013-12-31$22.4kus-gaap:InterestExpense
Income tax3 months2013-10-01 to 2013-12-31−$48.5kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2013-07-01 to 2013-12-31−$48.5kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-10-01 to 2013-12-31$26.4kus-gaap:NetIncomeLoss
Net income6 months2013-07-01 to 2013-12-31−$545.1kus-gaap:NetIncomeLoss
Diluted EPS3 months2013-10-01 to 2013-12-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2013-07-01 to 2013-12-31−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2013-07-01 to 2013-12-31−$101.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-12-31$736us-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-12-31$11.9kus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$11.9kus-gaap:Assets
Current liabilitiesAt period end2013-12-31$1.1mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2013-12-31−$1.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001354488-14-000725. Last ingested by Listed: Nov 14, 2026, 18:42 ET. Listed shows no prices and gives no investment advice.